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Abstract
Adenosine, a catabolite of ATP, displays a wide variety of effects in the heart including regulation of cardiac response to
myocardial ischemia and reperfusion injury. Nonetheless, the precise mechanism of adenosine-induced cardioprotection is
still elusive. Isolated Sprague-Dawley rat hearts underwent 30 min global ischemia and 120 min reperfusion using a
Langendorff apparatus. Both adenosine and acetylcholine treatment recovered the post-reperfusion cardiac function
associated with adenosine and muscarinic receptors activation. Simultaneous administration of adenosine and acetylcholine
failed to exert any additive protective effect, suggesting a shared mechanism between the two. Our data further revealed a
cross-talk between the adenosine and acetylcholine receptor signaling in reperfused rat hearts. Interestingly, the selective
M2 muscarinic acetylcholine receptor antagonist methoctramine significantly attenuated the cardioprotective effect of
adenosine. In addition, treatment with adenosine upregulated the expression and the maximal binding capacity of
muscarinic acetylcholine receptor, which were inhibited by the selective A1 adenosine receptor antagonist 8-Cyclopentyl-
1,3-dipropylxanthine (DPCPX) and the nitric oxide synthase inhibitor N
v-nitro-L-arginine methyl ester (L-NAME). These data
suggested a possible functional coupling between the adenosine and muscarinic receptors behind the observed
cardioprotection. Furthermore, nitric oxide was found involved in triggering the response to each of the two receptor
agonist. In summary, there may be a cross-talk between the adenosine and muscarinic receptors in ischemic/reperfused
myocardium with nitric oxide synthase might serve as the distal converging point. In addition, adenosine contributes to the
invigorating effect of adenosine on muscarinic receptor thereby prompting to regulation of cardiac function. These findings
argue for a potentially novel mechanism behind the adenosine-mediated cardioprotection.
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Introduction
Adenosine is an endogenous purine metabolite that may act as
acute ‘‘retaliatory’’ systems mediating immediate responses to
injurious stimuli and offer potential as targets for therapeutic
cardioprotection. Substantial evidence has accumulated that
adenosine is capable of rapidly responding to myocardial ischemic
stress and reperfusion insult, contributing to coronary hyperemia,
improved microcirculation and reduced infarct size [1–4]. Several
small-scale clinical studies have recently demonstrated that
administration of adenosine during reperfusion rescues ventricular
function and improves the overall clinical outcomes [5]. Adenosine
mediates various cardiovascular responses via its receptor subtypes
(A1AR, A2AAR, A2BAR, and A3AR), which are expressed in
different cell types in the heart and vessels, and are coupled to
different G proteins to trigger a range of physiological responses
[6]. Adenosine elicits its cardioprotection via activation of A1AR to
attenuate myocardial responsiveness to toxic effects of adrenergic
overstimulation [3]. Such antiadrenergic property of adenosine
plays an essential role in the regulation of autonomic nervous
activity.
It is well known that autonomic dysregulation in the heart,
which is manifested as suppressed vagal (parasympathetic) activity
in combination with increased sympathetic activity, leads to severe
cardiovascular sequelae including myocardial ischemia, hyperten-
sion, heart failure and arrhythmia [7,8]. In fact, the decreased
expression and impaired function of muscarinic acetylcholine
receptor (MAChR) may be responsible for the diminished vagal
activity. On the other hand, some studies have shown that beta-
blocker (eg. carvedilol) [9] and angiotensin-converting enzyme
inhibitors [10] restore vagal tone on heart failure partly by
increasing M2AChR (the main MAChR in mammalian heart).
Our previous study also has indicated that the exogenous
precursor of adenosine, namely adenine sulfate exerts cardiopro-
tection via the up-regulation of muscarinic receptor and
cholinergic nerve density [11].
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with parasympathetic nerve system [12]. In terms of cardiac
protection, adenosine infusion enhances cholinergic effects in
isolated canine atria [13]. Moreover, Silinsky E and colleagues
have shown that adenosine may promote acetylcholine secretion
in motor neurons [14]. However, there are few systematic
studies with regards to whether and how adenosine regulates
parasympathetic nerve system to ameliorate heart function.
Therefore, the present study will focus on the interaction
between adenosine and muscarinic receptors in the ischemic-
reperfused myocardium.
Materials and Methods
Ethics Statement
Adult male Sprague-Dawley rats were supplied by the
Experimental Animal Center of Xi’an Jiaotong University, China,
and weighing 180–220 g. This study was carried out in strict
accordance with the Guidelines on the Care and Use of
Laboratory Animals issued by the Chinese Council on Animal
Research and the Guidelines of Animal Care. The protocol was
approved by the ethical committee of Xi’an Jiaotong University.
All surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Langendorff-isolated Perfused Heart Preparation
Rats were sacrificed by cervical dislocation after anesthesia with
3% sodium pentobarbital (40 mg/kg, intraperitoneal injection),
and their hearts were excised rapidly and rinsed by immersion in
ice-cold Krebs-Henseleit buffer (KHB) (mM: NaCl 118.5, KCl
4.7, MgSO4 1.2, CaCl2 1.8, NaHCO3 25.0, and glucose 11.0 at
pH 7.35). Hearts were mounted on a non-recirculating Langen-
dorff apparatus (ML785B2, ADInstruments, Inc., MA, Australia)
and retrogradely perfused with warm (37uC), oxygenated (95%
O2,5 %C O 2) KHB at a constant pressure of 70 mmHg. The
organ chamber temperature was maintained at 37uC during the
experiment. A water-filled latex balloon was inserted through an
incision in the left atrium into the left ventricle via the mitral valve
and adjusted to a left ventricular end-diastolic pressure (LVEDP)
of 5–7 mmHg during initial equilibrium. The distal end of the
catheter was connected to a PowerLab 8/SP TM data acquisition
system (Chart 5.0 software, AD Instruments Inc., MA, Australia)
via a pressure transducer for continuous recording. Left ventric-
ular systolic function was assessed by recording the left-ventricular
developed pressure (LVDP), which was defined as the difference
between left-ventricular systolic pressure (LVSP) and LVEDP.
Heart rate and coronary flow rate were monitored simultaneously.
In each experiment, after 30 min of stabilization perfused with
KHB, hearts of all groups underwent 30 min global ischemia (zero
perfusion) and 120 min reperfusion.
Experimental Protocols
The hearts were randomly assigned to one of the following
treatments that were applied for the first 60 minutes of reperfusion:
(1) KHB (IR); (2) adenosine (Ado, 0.1 mM); (3) acetylcholine (ACh,
0.1 mM); (4) adenosine+acetylcholine; (5) selective antagonist for the
A1 adenosine receptor (A1AR) 8-Cyclopentyl-1,3-dipropylxanthine
(DPCPX, 1.0 mM); (6) selective antagonist for the M2 muscarinic
acetylcholine receptor (M2AChR) methoctramine (METH, 1.0 mM);
(7) non-specific nitric oxide synthase (NOS) inhibitor: N
v-nitro-L-
arginine methyl ester: (L-NAME, 0.1 mM); (8) Ado+DPCPX; (9)
ACh+DPCPX; (10) Ado+METH; (11) ACh+METH; (12) Ado+L-
NAME and (13) ACh+L-NAME (n=6 in each group). At the 60th
min after the onset of reperfusion, coronary effluent was collected
continuously for the lactate dehydrogenase (LDH) and nitric oxide
(NO) assay. At the end of reperfusion, each heart was quickly
removed and immediately frozen in liquid nitrogen and stored at
280uC for subsequent testing.
Western Blots
Frozen heart samples collected at the end of reperfusion were
transferred to an ice cold RIPA lysis buffer (Beyotime Biotech,
Nantong, China) containing phenylmethanesulfonyl fluoride and
homogenized with a tissue homogenizer. After centrifugation
(12,000 rpm, 5 min at 4uC), the tissue lysates were used in Western
blot analyses. Protein concentration was determined using the BCA
protein assay kit (Beyotime Biotech). Samples were boiled for 5 min
and then loaded on 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and electrotransferred to PVDF-
membrane, which was subsequently blocked with 5% skim milk
for 1 h at 37uC. Membranes were incubated with primary
antibodies directed against anti-b-actin and anti-M2 (1:200; Santa
Cruz, CA, USA) in 5% TBST at 4uC overnight. After washing
membranes with TBST for three times, membranes were incubated
with horseradish-peroxidase-conjugated secondary antibody
(1:2000; Bios, Beijing, China) for 1 h at 37uC. After being washed,
protein bands were shown using ECL-Plus reagent (Pierce,
Rockford, IL, USA) and quantified by scanning densitometry.
Radioligand Receptor Binding Assay
Myocardial tissues were finely minced in ice-cold Tris-HCl buffer
and then were homogenized at 4uC. After centrifugation, the
supernatant was filtered through cheesecloth and then re-centri-
fuged at 20,0006g for 30 min. The resulting pellet was gently
resuspended and samples were removed for protein determination
using the Coomassie Brilliant Blue method. Membrane suspensions
from either the atrium or ventricles were incubated with increasing
concentrations of [
3H] quinuclidinyl benzilate (QNB 0.1–6 nM, a
potent central muscarinic antagonist) to measure total binding.
Non-specific binding was defined in the presence of 2 mM atropine.
Specific binding was estimated as the difference between total and
non-specific binding. Membranes were filtered using a tissue
harvester through GF/B filters presoaked in sodium phosphate
buffer containing for 12 h. Individual filters were washed three
times with ice-cold buffer and dried in an incubator at 80uC. Once
dried, 5 mL of scintillation liquid (23 mM PPO, 0.8 mM POPOP,
10% v/v triton X-100 dissolved in toluene) was added. The filters
were left overnight before the radioactivity was measured by liquid
scintillation spectrometry.
Determination of LDH and NOx
Lactate dehydrogenase (LDH) in coronary effluent was
determined colorimetrically at 440 nm using a spectrophotometer
by the associated detection kits (Nanjing Jiancheng Bioengineering
Institute, NJBI, Niangjing, China). Data were expressed as units of
activity per liter coronary effluent (U/L). The index nitric oxide
production (NOx) in cardiac tissue was determined indirectly as
the concentration of nitrite from nitrates by the assay kit (NJBI,
Niangjing, China). Briefly, heart tissue was homogenized and
centrifuged at 100006g for 10 min. The supernatant was removed
and mixed with equal volume of Griess regent. After incubation
for 15 min at room temperature, absorbance was measured
spectrophotometrically at 550 nm.
Statistical Analysis
Values were presented as mean6standard error (SE). Coronary
flow rate and cardiac contractility data were analysed using
Adenosine and Muscarinic Receptors
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Newman-Keuls post-hoc test to compare differences in any
parameter between groups. Other data were analyzed with a
one-way ANOVA followed by a LSD post-hoc test. Significance
level was set at P,0.05.
Results
Effects of Adenosine/Acetylcholine on Cardiac Function
and LDH
Baseline cardiac functional parameters (heart rate, coronary
flow rate and LVDP) for various groups are shown in Table 1. No
difference was found in the pre-ischemic cardiac function among
experimental groups. After 30 min of global ischemia and
120 min of reperfusion, ischemic-reperfused hearts (IR) exhibited
a significant reduction in coronary flow rate (CFR) and LVDP
(expressed as the percentage of baseline). Both adenosine and
acetylcholine treatment recovered the post-reperfusion cardiac
function. Adenosine (Ado, 0.1 mM) dramatically improved CFR
and LVDP (P,0.01 vs. IR, Fig. 1A, B). Acetylcholine (ACh,
0.1 mM) produced a slight increase in CFR and marked
enhancement in LVDP (P,0.01 vs IR, Fig. 1A, B). Furthermore,
the effect of adenosine on CFR was more pronounced than that of
acetylcholine (82.364.5% for Ado vs. 50.366.8% for ACh,
P,0.01). However, little difference was observed in the improve-
ment of LVDP between Ado and ACh groups (70.567.3% for
Ado vs. 63.363.1% for ACh, P.0.05). Interestingly, simultaneous
administration of both adenosine and acetylcholine failed to exert
any additional protective effect over either agonist alone.
Myocardial damage was confirmed using LDH in coronary
effluent as an indicator of cell cytotoxicity. With the prolongation
of reperfusion time, both adenosine and acetylcholine treatment
significantly lessened the LDH release (13706111 for adenosine
and 15116155 for acetylcholine vs. 38766100 for IR, P,0.01).
When adenosine and acetylcholine were employed in combina-
tion, no additive protective effect was observed (Fig. 1C).
Effects of Adenosine/Acetylcholine and Receptors
Blockade on NOx Production
Treatment with adenosine and acetylcholine resulted in a
significant 109% and 123% increase in production of NOx in
myocardium compared with the IR group (P,0.01 vs. IR group),
respectively. There was no significant difference between the
adenosine and acetylcholine groups. When adenosine and
acetylcholine were administered in combination, little additive
Figure 1. Effects of adenosine/acetylcholine on cardiac func-
tion and LDH. (A) Adenosine/acetylcholine improved coronary flow
rate (CFR) in ischemic-reperfused rat hearts; (B) Adenosine/acetylcholine
improved left-ventricular developed pressure (LVDP) in ischemic-
reperfused rat hearts; (C) Adenosine/acetylcholine lessened the LDH
release in coronary effluent. IR: ischemic reperfusion; Ado: adenosine;
ACh: acetylcholine; IS: iscehmia.
*P,0.01 vs. IR;
#P,0.01 vs. Ado; NS: not
significance (n=6 in each group).
doi:10.1371/journal.pone.0025618.g001
Table 1. Baseline cardiodynamic data after 30 min of
equilibration to Langendorff perfusion.
Group HR (beat/min) CFR (mL/min) LVDP (mmHg)
IR 286617 12.160.8 81.2614
Ado 292623 12.661.4 89.2617
ACh 296623 12.560.8 91.0614
Ado + ACh 289613 12.460.8 89.2611
Ado + DPCPX 298619 12.161.2 85.866
ACh + DPCPX 279615 12.261.1 87.366
Ado + METH 300691 2 . 2 61.7 90.066
ACh + METH 305615 12.661.4 87.8612
Ado + L-NAME 286616 12.461.5 88.5617
ACh + L-NAME 300610 12.861.0 84.3612
Values are means 6 SE; n=6 in each group. HR: heart rate; CFR: coronary flow
rate; LVDP: left ventricular developed pressure. There were no significant
differences among groups in baseline cardiodynamic data (P.0.05).
doi:10.1371/journal.pone.0025618.t001
Adenosine and Muscarinic Receptors
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antagonist DPCPX (1.0 mM) and adenosine or the selective
M2AChR antagonist METH (1.0 mM) and adenosine was
performed. DPCPX abolished the increase of NOx afforded by
adenosine (P,0.01 vs. Ado group), but had no such effect on
acetylcholine (P.0.05 vs. ACh group). In the contrary, METH
blunted the increase of NOx mediated by adenosine and abolished
this effect of acetylcholine (P,0.01 vs. corresponding control,
Fig. 2B). DPCPX and METH alone had no appreciable effect on
NOx release (data not shown). These results indicated that the
effects of adenosine and acetylcholine on NOx release might likely
involve activation of A1AR and M2AChR, respectively. Interest-
ingly, M2AChR seemed to partially mediate the effect of
adenosine, and NOS possibly served as the distal common
pathway.
Effects of NOS Inhibitor on Adenosine/Acetylcholine-
mediated Cardioprotection
Co-administration of L-NAME, an inhibitor of NOS and
adenosine, L-NAME notably blocked the adenosine-induced
improvement in CRF and LVDP (Fig. 3A, B). L-NAME also
reversed the inhibitory effect of adenosine on LDH (Fig. 3C).
Similarly, Co-administration of L-NAME and acetylcholine, L-
NAME abrogated the acetylcholine-induced ameliorative effects in
the reperfused hearts. Meanwhile, there were no significant
differences in the effects of NOS inhibitor between adenosine
and acetylcholine-mediated cardioprotection. Hence, NOS might
Figure 2. Effects of adenosine/acetylcholine and receptors
blockade on NOx production. (A) Adenosine/acetylcholine in-
creased the production of NOx in ischemic-reperfused rat hearts; (B)
A1AR antagonist DPCPX abolished the increase of NOx afforded by
adenosine. M2AChR antagonist METH blunted the increase of NOx
mediated by adenosine and abolished this effect of acetylcholine.
*P,0.01 vs. IR;
#P,0.01 vs. Ado;
&P,0.01 vs. ACh; NS: not significance
(n=6 in each group).
doi:10.1371/journal.pone.0025618.g002
Figure 3. Effects of NOS Inhibitor on adenosine/acetylcholine-
mediated cardioprotection. (A) NOS inhibitor L-NAME abolished the
increase in coronary flow rate (CFR) mediated by adenosine/acetylcho-
line; (B) NOS inhibitor L-NAME abolished the left-ventricular developed
pressure (LVDP) improvement mediated by adenosine/acetylcholine; (C)
NOS inhibitor L-NAME abolished the decrease in LDH release mediated
by adenosine/acetylcholine in coronary effluent. Ado: adenosine; ACh:
acetylcholine; IS: iscehmia.
**P,0.01 vs. Ado;
##P,0.01 vs. ACh (n=6 in
each group).
doi:10.1371/journal.pone.0025618.g003
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both adenosine and acetylcholine.
Effects of A1AR and M2AChR Blockade on Adenosine-
mediated Cardioprotection
Co-administration of the selective A1AR antagonist DPCPX
(1.0 mM) and adenosine or the selective M2AChR antagonist
METH (1.0 mM) and adenosine was performed. Our result
showed that DPCPX blunted the coronary vasodilatation afforded
by adenosine (P,0.01 vs. Ado group Fig. 4A); METH had little
effect on CRF. Furthermore, DPCPX abolished adenosine-elicited
protective effect on myocardial contractile recovery. Surprisingly,
METH dampened the effect of adenosine on LVDP (P,0.01 vs.
Ado group Fig. 4B). In addition, both DPCPX and METH
suppressed the adenosine-mediated decrease in LDH release
(34896135 U/L for Ado+DPCPX vs. 13706111 U/L for Ado
group, P,0.01; 22356175 U/L for Ado+METH vs. Ado group,
P,0.05, Fig. 4C). Treatment with DPCPX or METH alone had
no effect on cardiac function (data not shown). Thus, DPCPX
nearly abolished the cardioprotection induced by adenosine
during reperfusion. Intriguingly, METH was able to partially
reverse the protective effects of adenosine.
Effects of A1AR and M2AChR Blockade on Acetylcholine-
mediated Cardioprotection
Simultaneous treatment with the selective A1AR antagonist
DPCPX (1.0 mM) and acetylcholine or the selective M2AChR
antagonist METH (1.0 mM) and acetylcholine was performed.
Our data revealed that DPCPX was unable to attenuate the
acetylcholine-induced cardioprotection (P.0.05 vs. ACh group,
Fig. 5). METH abolished the protective effects of acetylcholine,
which abrogated the acetylcholine-mediated increase in CFR and
LVDP (P,0.01 vs. ACh group, Fig. 5A, B), as well as the decrease
in LDH release (P,0.01 vs. ACh group, Fig. 5C). Thus,
acetylcholine participated in prevention of reperfusion injury
mostly through M2AChR activation. DPCPX failed to inhibit its
cardioprotection.
Adenosine Increased the Protein Expression of M2AChR
The protein expression of M2AChR was determined by
Western blot. Adenosine treatment at reperfusion significantly
increased the protein level of M2AChR compared with the IR
group (P,0.01 vs. IR group, Fig. 6). Co-treatment with DPCPX or
L-NAME abolished adenosine-induced increase in M2AChR
protein expression (P,0.01 vs. Ado group). Treatment with either
DPCPX or L-NAME alone exerted little effect on protein
expression of M2AChR (data not shown). Thus, adenosine
increased the protein level of M2AChR mainly through A1AR
activation and NOS pathway may be involved in such effect.
Adenosine Increased the Bmax of MAChR
A radioligand-receptor binding assay was performed to evaluate
the capacity of the muscarinic receptor. Scatchard analysis of the
saturation curves demonstrated the density of muscarinic receptors
by the maximal binding capacity (Bmax). Adenosine at reperfusion
significantly increased the Bmax (Ado group: 245633 fmol/mg in
atria and 9369 fmol/mg in ventricle, vs. IR group: 157622 fmol/
mg in atria and 6969 fmol/mg in ventricle, P,0.01, Fig. 7). Both
DPCPX and L-NAME inhibited adenosine-induced Bmax im-
provement (P,0.01 vs. Ado group in atria; P,0.05 vs. Ado group
in ventricle). These results were consistent with the data from the
M2AChR protein expression. Treatment with DPCPX or L-
NAME alone had no effects on Bmax of MAChR (data not shown).
Figure 4. Effects of A1AR and M2AChR blockade on adenosine-
mediated cardioprotection. (A) DPCPX abolished the increase in
coronary flow rate (CFR) mediated by adenosine; METH had little effect
on CRF. (B) DPCPX abolished the left-ventricular developed pressure
(LVDP) improvement mediated by adenosine; METH dampened the
effect on LVDP (C) DPCPX and METH suppressed the decrease in LDH
release mediated by adenosine in coronary effluent. IR: ischemic
reperfusion; Ado: adenosine; IS: iscehmia.
*P,0.05,
**P,0.01 vs. IR;
#P,0.05,
## P,0.01 vs. Ado (n=6 in each group).
doi:10.1371/journal.pone.0025618.g004
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through A1AR activation and NOS pathway may be involved in
such effects.
Discussion
The present experiments showed that both adenosine and
acetylcholine ameliorated cardiac function in the reperfused rat
heart. Simultaneous administration of adenosine and acetylcholine
failed to offer any additional beneficial effect. Further, we found
that NOS might act in a shared pathway with a common
converging point. Intriguingly, selective M2AChR antagonist
partially attenuated the cardioprotective effect of adenosine.
Otherwise, adenosine contributed to the invigorating effect on
muscarinic receptors. These data depicted a possible functional
coupling between the adenosine and muscarinic receptors in
mediating cardioprotection in the rat heart.
It has been convincingly reported that A1AR is essential to the
adenosine-induced cardioprotection against reperfusion injury.
Administration of A1AR blocker DPCPX abolishes the infarct-
limiting effect in isolated rabbit hearts following global ischemia-
reperfusion [5]. The finding is further supported in animal models
with a complete loss of cardioprotection in A1AR knock-out mice
[15]. In addition, activation of A1AR by endogenous adenosine
during reperfusion has also been shown to be protective in mouse
hearts [16]. In agreement with previous studies, an obvious
improvement in cardiac function is achieved by adenosine in
reperfused rat hearts, and the A1AR antagonist DPCPX abolishes
this effects. On the other hand, it is more novel that the M2AChR
antagonist METH suppresses the adenosine-induced cardiopro-
tection partly.
Several lines of evidence suggest that adenosine is cardiopro-
tective in patients with congestive heart failure and ischemic heart
disease via attenuation of catecholamine release and metabolic
responses to b-adrenergic stimulation, which is mainly mediated
by A1AR [17]. Pelleg and colleagues elucidated the anti-
adrenergic actions of adenosine both in vivo and in vitro. In the
presence of isoproterenol (0.2 mg/kg/min), adenosine (0.01–
0.1 mM/kg) given as a rapid bolus potentiated the significantly
negative chronotropic action in rats. Similarly, in isolated perfused
hearts, adenosine administration attenuated isoproterenol-induced
chronotropic and inotropic effects [18]. In contrast, our previous
study showed that adenine sulfate (the exogenous precursor of
adenosine) reduced cardiac dysfunction following coronary
ligation accompanied by increasing the distribution density of
Figure 5. Effects of A1AR and M2AChR blockade on acetylcho-
line-mediated cardioprotection. (A) METH abolished the increase in
coronary flow rate (CFR) mediated by acetylcholine; (B) METH abolished
the left-ventricular developed pressure (LVDP) improvement mediated
by acetylcholine; (C) METH abolished the decrease in LDH release
mediated by acetylcholine in coronary effluent. IR: ischemic reperfusion;
ACh: acetylcholine; IS: iscehmia.
*P,0.05,
**P,0.01 vs. IR;
&P,0.05,
&&P,0.01 vs. ACh; NS: not significance (n=6 in each group).
doi:10.1371/journal.pone.0025618.g005
Figure 6. Effects of adenosine on the protein expression of
M2AChR. Adenosine increased the protein level of M2AChR and DPCPX
or L-NAME abolished this effect. IR: ischemic reperfusion; Ado:
adenosine;
*P,0.01 vs. IR;
#P,0.01 vs. Ado (n=6 in each group).
doi:10.1371/journal.pone.0025618.g006
Adenosine and Muscarinic Receptors
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post-infarction rat hearts [11]. In our present study, we identified
the adenosine and muscarinic receptor interaction in rat hearts.
Our data further revealed that activation of either adenosine or
muscarinic receptor resulted in a significant improvement in
cardiac function against reperfusion injury (Fig. 1), which was
abolished by antagonism against either A1AR or M2AChR (Fig. 4).
Of particular interest is the observation that the M2AChR
antagonist METH also blunts the adenosine-induced cardiopro-
tection (i.e., increase in LVDP and decrease in LDH), although it
failed to antagonize the coronary vasodilatory effect (Fig. 4). To
the contrary, the A1AR antagonist DPCPX had no effects on
acetylcholine-mediated protection (Fig. 5). Furthermore, adeno-
sine treatment overtly elevated protein expression (Fig. 6) and Bmax
of MAChR (Fig. 7), which was abolished by the selective A1AR
antagonist DPCPX. These data represent the first piece of
evidence on a cross-talk between adenosine and muscarinic
receptors.
Simultaneous administration of both adenosine and acetylcho-
line failed to exert an additive protective effect over either agonist
alone, suggesting a shared mechanism with a possible converging
check-point (Fig. 1). Indeed, it appears that A1AR and M2AChR
activation may act in concert to afford cardioprotection. It has
been demonstrated that adenosine can induce NO release in a
wide variety of cells including endothelial cells, smooth muscle
cells and cardiomyocytes. Adenosine increases NO production
through activation of adenosine receptors and NOS. NO has been
known to play a crucial role in the protective effect of adenosine on
mitochondrial oxidant damage [19]. Likewise, Yao and Gross
examined the involvement of NOS in the anti-infarct effect of
acetylcholine in the canine heart, while their results indicated that
acetylcholine-elicited protection may be blocked by L-NAME
[20]. In this study, we found that adenosine and acetylcholine
independently increased NO release and rescued myocardial
reperfusion injury. This effect was blocked by the appropriate
receptor antagonists as well as the NOS inhibitor L-NAME,
indicating a pivotal role of NO as a distal effector for
cardioprotection (Fig. 2, 3). Taken together, the data presented
in this study implicates an integral role for the NO in the signal
pathway following adenosine and muscarinic receptor activation.
In our present experiment, adenosine treatment improved
muscarinic receptors and contractile function in reperfused
myocardium. Based on data from our current study and others,
it is plausible to speculate that adenosine-mediated cardioprotec-
tion is associated with not only an anti-adrenergic effect, but also
elevated parasympathetic tone. This amelioration of cardiovascu-
lar function may be a potentially novel mechanism of adenosine.
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